Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma

Maja V. Maraldo, Nils P. Brodin, Ivan R. Vogelius, Marianne C. Aznar, Per Munck Af Rosenschöld, Peter M. Petersen, Lena Specht

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Purpose: Hodgkin lymphoma (HL) survivors are known to have increased cardiac mortality and morbidity. The risk of developing cardiovascular disease after involved node radiotherapy (INRT) is currently unresolved, inasmuch as present clinical data are derived from patients treated with the outdated mantle field (MF) technique. Methods and Materials: We included all adolescents and young adults with supradiaphragmatic, clinical Stage I-II HL treated at our institution from 2006 to 2010 (29 patients). All patients were treated with chemotherapy and INRT to 30 to 36 Gy. We then simulated a MF plan for each patient with a prescribed dose of 36 Gy. A logistic dose-response curve for the 25-year absolute excess risk of cardiovascular disease was derived and applied to each patient using the individual dose-volume histograms. Results: The mean doses to the heart, four heart valves, and coronary arteries were significantly lower for INRT than for MF treatment. However, the range in doses with INRT treatment was substantial, and for a subgroup of patients, with lymphoma below the fourth thoracic vertebrae, we estimated a 25-year absolute excess risk of any cardiac event of as much as 5.1%. Conclusions: Our study demonstrates a potential for individualizing treatment by selecting the patients for whom INRT provides sufficient cardiac protection for current technology; and a subgroup of patients, who still receive high cardiac doses, who would benefit from more advanced radiation technique.

Original languageEnglish (US)
Pages (from-to)1232-1237
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume83
Issue number4
DOIs
StatePublished - Jul 15 2012
Externally publishedYes

Fingerprint

Hodgkin Disease
radiation therapy
Earth mantle
Cardiovascular Diseases
Radiotherapy
dosage
subgroups
heart valves
vertebrae
Thoracic Vertebrae
mortality
Heart Valves
logistics
chemotherapy
arteries
histograms
Survivors
Young Adult
Lymphoma
Coronary Vessels

Keywords

  • Cardiovascular disease
  • Hodgkin lymphoma
  • Involved field radiotherapy
  • Mantle field

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma. / Maraldo, Maja V.; Brodin, Nils P.; Vogelius, Ivan R.; Aznar, Marianne C.; Munck Af Rosenschöld, Per; Petersen, Peter M.; Specht, Lena.

In: International Journal of Radiation Oncology Biology Physics, Vol. 83, No. 4, 15.07.2012, p. 1232-1237.

Research output: Contribution to journalArticle

Maraldo, Maja V. ; Brodin, Nils P. ; Vogelius, Ivan R. ; Aznar, Marianne C. ; Munck Af Rosenschöld, Per ; Petersen, Peter M. ; Specht, Lena. / Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma. In: International Journal of Radiation Oncology Biology Physics. 2012 ; Vol. 83, No. 4. pp. 1232-1237.
@article{23b570cc3ce74c2c890b373cf7caf403,
title = "Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma",
abstract = "Purpose: Hodgkin lymphoma (HL) survivors are known to have increased cardiac mortality and morbidity. The risk of developing cardiovascular disease after involved node radiotherapy (INRT) is currently unresolved, inasmuch as present clinical data are derived from patients treated with the outdated mantle field (MF) technique. Methods and Materials: We included all adolescents and young adults with supradiaphragmatic, clinical Stage I-II HL treated at our institution from 2006 to 2010 (29 patients). All patients were treated with chemotherapy and INRT to 30 to 36 Gy. We then simulated a MF plan for each patient with a prescribed dose of 36 Gy. A logistic dose-response curve for the 25-year absolute excess risk of cardiovascular disease was derived and applied to each patient using the individual dose-volume histograms. Results: The mean doses to the heart, four heart valves, and coronary arteries were significantly lower for INRT than for MF treatment. However, the range in doses with INRT treatment was substantial, and for a subgroup of patients, with lymphoma below the fourth thoracic vertebrae, we estimated a 25-year absolute excess risk of any cardiac event of as much as 5.1{\%}. Conclusions: Our study demonstrates a potential for individualizing treatment by selecting the patients for whom INRT provides sufficient cardiac protection for current technology; and a subgroup of patients, who still receive high cardiac doses, who would benefit from more advanced radiation technique.",
keywords = "Cardiovascular disease, Hodgkin lymphoma, Involved field radiotherapy, Mantle field",
author = "Maraldo, {Maja V.} and Brodin, {Nils P.} and Vogelius, {Ivan R.} and Aznar, {Marianne C.} and {Munck Af Rosensch{\"o}ld}, Per and Petersen, {Peter M.} and Lena Specht",
year = "2012",
month = "7",
day = "15",
doi = "10.1016/j.ijrobp.2011.09.020",
language = "English (US)",
volume = "83",
pages = "1232--1237",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma

AU - Maraldo, Maja V.

AU - Brodin, Nils P.

AU - Vogelius, Ivan R.

AU - Aznar, Marianne C.

AU - Munck Af Rosenschöld, Per

AU - Petersen, Peter M.

AU - Specht, Lena

PY - 2012/7/15

Y1 - 2012/7/15

N2 - Purpose: Hodgkin lymphoma (HL) survivors are known to have increased cardiac mortality and morbidity. The risk of developing cardiovascular disease after involved node radiotherapy (INRT) is currently unresolved, inasmuch as present clinical data are derived from patients treated with the outdated mantle field (MF) technique. Methods and Materials: We included all adolescents and young adults with supradiaphragmatic, clinical Stage I-II HL treated at our institution from 2006 to 2010 (29 patients). All patients were treated with chemotherapy and INRT to 30 to 36 Gy. We then simulated a MF plan for each patient with a prescribed dose of 36 Gy. A logistic dose-response curve for the 25-year absolute excess risk of cardiovascular disease was derived and applied to each patient using the individual dose-volume histograms. Results: The mean doses to the heart, four heart valves, and coronary arteries were significantly lower for INRT than for MF treatment. However, the range in doses with INRT treatment was substantial, and for a subgroup of patients, with lymphoma below the fourth thoracic vertebrae, we estimated a 25-year absolute excess risk of any cardiac event of as much as 5.1%. Conclusions: Our study demonstrates a potential for individualizing treatment by selecting the patients for whom INRT provides sufficient cardiac protection for current technology; and a subgroup of patients, who still receive high cardiac doses, who would benefit from more advanced radiation technique.

AB - Purpose: Hodgkin lymphoma (HL) survivors are known to have increased cardiac mortality and morbidity. The risk of developing cardiovascular disease after involved node radiotherapy (INRT) is currently unresolved, inasmuch as present clinical data are derived from patients treated with the outdated mantle field (MF) technique. Methods and Materials: We included all adolescents and young adults with supradiaphragmatic, clinical Stage I-II HL treated at our institution from 2006 to 2010 (29 patients). All patients were treated with chemotherapy and INRT to 30 to 36 Gy. We then simulated a MF plan for each patient with a prescribed dose of 36 Gy. A logistic dose-response curve for the 25-year absolute excess risk of cardiovascular disease was derived and applied to each patient using the individual dose-volume histograms. Results: The mean doses to the heart, four heart valves, and coronary arteries were significantly lower for INRT than for MF treatment. However, the range in doses with INRT treatment was substantial, and for a subgroup of patients, with lymphoma below the fourth thoracic vertebrae, we estimated a 25-year absolute excess risk of any cardiac event of as much as 5.1%. Conclusions: Our study demonstrates a potential for individualizing treatment by selecting the patients for whom INRT provides sufficient cardiac protection for current technology; and a subgroup of patients, who still receive high cardiac doses, who would benefit from more advanced radiation technique.

KW - Cardiovascular disease

KW - Hodgkin lymphoma

KW - Involved field radiotherapy

KW - Mantle field

UR - http://www.scopus.com/inward/record.url?scp=84862690618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862690618&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2011.09.020

DO - 10.1016/j.ijrobp.2011.09.020

M3 - Article

VL - 83

SP - 1232

EP - 1237

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -